Component

Human glioblastoma stem-cell t6A and translation

Context-specific entity; species, compartment and exposure are stated on each claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Targeting YRDC reduced t6A, translation and tumor growth in glioblastoma stem-cell cultures and in vivo tumor models.

    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_access
    Primary abstract
    experimental_model
    CRISPR screen, cultured glioblastoma stem cells and xenografts.
    limitations
    Genetic targeting of YRDC is distinct from nutritional restriction and from a demonstrated human cancer treatment.
    nutrient_topic
    L-Threonine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · L-Threonine
    plain_language
    A tumor model depended on the machinery that uses threonine to modify tRNA.
    primary_references
    Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming. · 2024 · https://pubmed.ncbi.nlm.nih.gov/38519786/ · DOI 10.1038/s43018-024-00748-7
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    L-Threonine: translation, intestinal barrier, metabolism and cross-nutrient mechanisms (2026-09-19) · lines 362–368

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · CRISPR screen, cultured glioblastoma stem cells and xenografts. · source_derived_draft · unverified_draft

    ## l-threonine-yrdc-glioblastoma A tumor model depended on the machinery that uses threonine to modify tRNA. Targeting YRDC reduced t6A, translation and tumor growth in glioblastoma stem-cell cultures and in vivo tumor models. Model: CRISPR screen, cultured glioblastoma stem cells and xenografts. Limitations: Genetic targeting of YRDC is distinct from nutritional restriction and from a demonstrated human cancer treatment. Evidence access: Primary abstract Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming. · 2024 · https://pubmed.ncbi.nlm.nih.gov/38519786/ · DOI 10.1038/s43018-024-00748-7
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards